Octagon Capital Advisors LP / RCUS
Octagon Capital Advisors LP’s Arcus Biosciences Inc Position
Does Octagon Capital Advisors LP own Arcus Biosciences Inc (RCUS)? Not currently — the last reported position was 1.87M shares worth $36M in Q4 2023; the fund’s latest 13F (Q1 2026) no longer reports it.
Position Value
$36M
Q4 2023
Shares
1.87M
% of Portfolio
+5.71%
Quarters Held
13
position exited
Position History RCUS
Reported value by quarter
| Quarter | Shares | Value | % of Portfolio |
|---|---|---|---|
| Q4 2023 | 1.87M | $36M | +5.71% |
| Q3 2023 | 1.97M | $35M | +5.43% |
| Q2 2023 | 1.97M | $40M | +5.56% |
| Q1 2023 | 2.17M | $40M | +5.70% |
| Q4 2022 | 2.48M | $51M | +7.99% |
| Q3 2022 | 2.67M | $70M | +12.05% |
| Q2 2022 | 2.67M | $68M | +18.06% |
| Q1 2022 | 2.49M | $79M | +16.99% |
| Q4 2021 | 2.10M | $85M | +16.50% |
| Q3 2021 | 970.2K | $34M | +8.33% |
| Q2 2021 | 760.2K | $21M | +4.32% |
| Q1 2021 | 400.0K | $11M | +4.23% |
| Q4 2020 | 300.0K | $8M | +2.70% |
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Octagon Capital Advisors LP’s full portfolio or all institutional holders of RCUS.